Upstream Processing

The expansion at Seqirus’ Holly Springs, N.C., manufacturing facility will support the formulation and fill/finish of influenza vaccines.

Extensive work has greatly expanded the possibilities for fetal bovine serum sourcing.

908 Devices and CPI have formed a collaboration to optimize cell culture media to allow for improved process control.

Workforce training is crucial for biopharmaceutical manufacturing.

The growing demand for antibody and other bio-therapeutics will require long-term scale-up solutions.

Flexible and efficient methods are needed for biopharmaceutical manufacturing.

The use of bioengineering offers practical tools for the evolution of host cells.

Recent trends in data analytics highlight the use of modeling techniques to improve process control and monitoring in biopharmaceutical production.

The growing use of automation and digitalization technologies push cell culture bioprocessing forward.

Modeling techniques can improve process control and monitoring in biopharmaceutical production.

Upstream processing is better optimized with the help of automated workflows.

FUJIFILM Irvine Scientific’s new manufacturing facility in Tilburg, the Netherlands, is now fully operational.

Sartorius will invest approximately €270 million (US$305 million) to expand its biopharmaceutical manufacturing activities in South Korea’s biopharm hub.

Lonza is expanding its microbial development capabilities at its Visp, Switzerland, site to support clinical and commercial drug development programs.

The adoption of perfusion cell culture continues to advance with the help of PAT tools.

Large-scale single-use bioreactors prove successful as limits are tested.

SUB bioreactor performance has had seen its limits and successes.

Advancements in bioprocessing technologies test microbial fermentation adaptability.

The benefits of single-use technologies for upstream viral-vector processes clearly outweigh their disadvantages.

Catalent Biologics has launched its new cell line expression technology, GPEx Lightning, which aims to shorten drug substance development timelines by up to three months.

The collaboration continues as the companies design bioprocess impurity reagent sets to detect residual HCP from HEK 293 cells.

The acquisition of Intermountain Life Sciences will double Cytiva’s capacity for buffers and liquid cell culture media at its manufacturing site in Logan, Utah.

Cell-free expression is promising in preclinical applications, but still presents challenges to scale up for commercial production.

VectorY, a Netherlands-based biotechnology company, has been selected as the European winner of MilliporeSigma’s 2021 Advance Biotech Grant Program.

Demand for recombinant microorganism-based cell culture supplements is rising on the back of lower contamination risk.